Macquarie Group Ltd. reduced its stake in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 30.3% during the 4th quarter, Holdings Channel reports. The firm owned 23,000 shares of the biotechnology company’s stock after selling 10,000 shares during the period. Macquarie Group Ltd.’s holdings in Sarepta Therapeutics were worth $1,280,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of SRPT. Nationwide Fund Advisors boosted its position in shares of Sarepta Therapeutics by 11.7% in the 3rd quarter. Nationwide Fund Advisors now owns 32,906 shares of the biotechnology company’s stock worth $1,493,000 after purchasing an additional 3,440 shares during the last quarter. Prudential Financial Inc. bought a new position in shares of Sarepta Therapeutics in the 3rd quarter worth $266,000. Sei Investments Co. bought a new position in shares of Sarepta Therapeutics in the 3rd quarter worth $1,013,000. New York State Common Retirement Fund boosted its position in shares of Sarepta Therapeutics by 14.1% in the 3rd quarter. New York State Common Retirement Fund now owns 63,300 shares of the biotechnology company’s stock worth $2,871,000 after purchasing an additional 7,800 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Sarepta Therapeutics by 18.0% in the 3rd quarter. Rhumbline Advisers now owns 72,543 shares of the biotechnology company’s stock worth $3,291,000 after purchasing an additional 11,081 shares during the last quarter. Institutional investors and hedge funds own 84.98% of the company’s stock.
SRPT stock opened at $71.74 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 12.96 and a current ratio of 13.91. The stock has a market cap of $4,805.80, a price-to-earnings ratio of -43.74 and a beta of 1.29. Sarepta Therapeutics Inc has a 1-year low of $28.14 and a 1-year high of $84.37.
Several research analysts have recently issued reports on the company. JPMorgan Chase raised their price target on Sarepta Therapeutics from $75.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 14th. Royal Bank of Canada restated a “buy” rating and issued a $91.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, March 14th. BidaskClub upgraded Sarepta Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 15th. SunTrust Banks raised their price target on Sarepta Therapeutics to $95.00 and gave the stock a “buy” rating in a research report on Friday, March 16th. Finally, Morgan Stanley lowered Sarepta Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $64.00 to $87.00 in a research report on Wednesday, March 21st. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $78.87.
ILLEGAL ACTIVITY NOTICE: This report was reported by Ticker Report and is the property of of Ticker Report. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3337611/macquarie-group-ltd-sells-10000-shares-of-sarepta-therapeutics-inc-srpt.html.
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.